share_log

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax製藥 | 10-K/A:年度報表(修正版)
美股SEC公告 ·  10/11 05:10

牛牛AI助理已提取核心訊息

Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax藥品公司,一家處於臨床前階段的藥品公司,截至2022年12月31日的年度淨虧損爲2170萬美元,而上一年度的淨虧損爲1210萬美元。該公司的累積赤字達到了大約4440萬美元。儘管虧損,Virpax擁有約1900萬美元的現金儲備。該公司正與可能造成高達3500萬美元損失的訴訟進行訴訟,但已爲此目的提取了200萬美元。Virpax的主要資本來源是通過發行股票,包括2021年成功的首次公開發行(IPO)和一次在主承銷的公開發行。該公司的基本報表已根據其將繼續作爲持續經營實體的假設進行準備,儘管由於持續虧損和訴訟不確定性,存在重大疑慮。Virpax專注於開發非阿片類疼痛管理治療和中樞神經系統疾病治療。該公司依賴第三方合同製造組織(CMOs)進行生產,並已簽訂各種研究和許可協議以推進其產品候選物。
Virpax藥品公司,一家處於臨床前階段的藥品公司,截至2022年12月31日的年度淨虧損爲2170萬美元,而上一年度的淨虧損爲1210萬美元。該公司的累積赤字達到了大約4440萬美元。儘管虧損,Virpax擁有約1900萬美元的現金儲備。該公司正與可能造成高達3500萬美元損失的訴訟進行訴訟,但已爲此目的提取了200萬美元。Virpax的主要資本來源是通過發行股票,包括2021年成功的首次公開發行(IPO)和一次在主承銷的公開發行。該公司的基本報表已根據其將繼續作爲持續經營實體的假設進行準備,儘管由於持續虧損和訴訟不確定性,存在重大疑慮。Virpax專注於開發非阿片類疼痛管理治療和中樞神經系統疾病治療。該公司依賴第三方合同製造組織(CMOs)進行生產,並已簽訂各種研究和許可協議以推進其產品候選物。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。